Lupin Pharmaceuticals Inc, a wholly owned subsidiary of Mumbai-based Lupin Ltd, has forayed into the US pediatric segment by inking an agreement with Allergan Inc to promote 'Zymar' in that country.
Zymar was approved by the US Food & Drug Administration in March 2003 as the first fourth generation olphthalmic fluoroquinolone to enter the market, the company said in a release on Monday.
Lupin Pharma Inc president Vinita Gupta said: "We are pleased to enter into this agreement with Allergan as we launch our presence in the US pediatric speciality segment."
Zymar is already the number one prescribed olphthalmic fluoroquinolone among eye care professionals in the US.
As per the agreement, the product, which is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria, will be promoted by pediatric sales force of Lupin Pharmaceuticals Inc to high volume pediatric prescribers.
© 2025